Concomitant Adjuvant Chemoradiotherapy with Weekly Low-dose Cisplatin for High-risk Squamous Cell Carcinoma of the Head and Neck: a Phase II Prospective Trial

Rampino, Monica; Ricardi, Umberto; Muñoz, F. Longo; Reali, Alessia; Barone, C.; Musu, A.R.; Balcet, Vittoria; Franco, Pierfrancesco; Grillo, R.; Bustreo, Sara; Pecorari, Giancarlo; Cavalot, A; Garzino-Demo, Paolo; Ciuffreda, Libero; Ragona, Riccardo; Schena, Marina

doi:10.1016/j.clon.2010.09.004

Cited by 38 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine single-arm studies evaluated the efficacy of adjuvant CRT. [23][24][25][26][27][28][29][30][31] Of these, six were prospective trials. 23,24,26,28,30,31 Data gathered in these studies covered a period from 1980 to 2009.…”

Section: Literature Search Resultsmentioning

confidence: 99%

Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases

Lin

Varvares

2015

Head Neck

View full text Add to dashboard Cite

show abstract

Section: Literature Search Resultsmentioning

confidence: 99%

Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases

Lin

Varvares

2015

Head Neck

View full text Add to dashboard Cite

show abstract

“…Radiotherapy (RT) is a standard of care for head and neck cancer (HNC) patients in both the definitive and postoperative settings [1,2]. Combined modality treatment including RT and chemotherapy (CT) and/or bio-therapy is a well-established option providing a survival advantage over radiation alone [3,4].…”

Section: Introductionmentioning

confidence: 99%

Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer

et al. 2017

View full text Add to dashboard Cite

Oral mucositis (OM) is a common acute side effect during radiotherapy treatments for head and neck cancer (HNC), with a potential impact on patient's compliance to therapy, quality of life (QoL) and clinical outcomes. Its timely and appropriate management is of paramount importance. Several quantitative scoring scales are available to properly assess OM and its influence on patient-reported outcomes (PROs) and QoL. We prospectively assessed OM in a cohort of HNC patients submitted to radiation using the Oral Mucositis Assessment Scale (OMAS), while its impact on PROs and QoL was evaluated employing the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN) and the Functional Assessment of Cancer Therapy-Head and Neck Cancer (FACT-HN). Evaluation of OMAS scores highlighted a progressive increase in OM during treatment and a partial recovery after the end of radiation. These trends were correlated to PROs and QoL as evaluated with OMWQ-HN and FACT-HN questionnaires. In the present study, we provided a quantitative assessment of OM, PROs and QoL in HNC patient undergoing radiotherapy, potentially useful for future comparison.

show abstract

“…CDDP is expected to have a radiosensitizing effect when it is administered every week during radiation therapy and the dose intensity of weekly CDDP (40 mg/m 2 /week) is higher than that of 3-weekly CDDP (33 mg/m 2 /week). In fact, promising results of post-operative weekly CDDP þ RT were reported in two prospective trials (5,6). In addition, weekly CDDP þ RT has several advantages over 3-weekly CDDP þ RT in terms of safety and toxicity.…”

Section: Introductionmentioning

confidence: 90%

Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008)

Kunieda

Kiyota

Tahara

et al. 2014

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

A randomized Phase II/III study was launched in Japan to evaluate the non-inferiority of concurrent chemoradiotherapy with weekly cisplatin (40 mg/m 2 ) compared with concurrent chemoradiotherapy with 3-weekly cisplatin (100 mg/m 2 ) for post-operative high-risk patients with locally advanced squamous cell carcinoma of head and neck. This study began in October 2012, and a total of 260 patients will be accrued from 18 institutions within 5 years. The primary endpoint of the Phase II part is proportion of treatment completion and that of the Phase III part is overall survival. The secondary endpoints are relapse-free survival, local relapse-free survival, nutrition-support-free survival, non-hospitalized treatment period during permissible treatment period and adverse events. This trial was registered at the UMIN Clinical Trials Registry as UMIN 000009125 [http://www.umin.ac.jp/ctr/].

show abstract

Concomitant Adjuvant Chemoradiotherapy with Weekly Low-dose Cisplatin for High-risk Squamous Cell Carcinoma of the Head and Neck: a Phase II Prospective Trial

Cited by 38 publications

References 27 publications

Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases

Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases

Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer

Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008)

Contact Info

Product

Resources

About